Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06395285 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
A Phase 1 study of ROSAH, sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT06395285 is a Phase 1 study of ROSAH that is actively recruiting participants, run by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm). The registered enrollment target is 12 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06395285, a Phase 1 study of ROSAH, is actively recruiting participants, sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Conditions Studied
Interventions
- DRUG DF-003
Study Locations (4)
Maryland
- National Institutes of Health Clinical Center - Bethesda
North Carolina
- Duke Eye Center - Duke University Hospital - Durham
Utah
- John A. Moran Eye Center - University of Utah Health - Salt Lake City
New South Wales
- Save Sight Institute - University of Sydney Eye Hospital - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06395285
The ClinicalTrials.gov registry entry for NCT06395285 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ROSAH appearing as the primary indexed condition, and to 1 intervention - of which DF-003 is the first listed.
NCT06395285 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, North Carolina, Utah.
Frequently Asked Questions
What is clinical trial NCT06395285 about?
NCT06395285 is a clinical study titled "Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients". The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
What is the current status of trial NCT06395285?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-27. Estimated completion is 2026-05.
What conditions does trial NCT06395285 study?
This clinical trial studies the following conditions: ROSAH.
What interventions are being tested in trial NCT06395285?
The interventions under investigation include: DF-003 (DRUG).
Who is sponsoring clinical trial NCT06395285?
This trial is sponsored by Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06395285 being conducted?
This trial has 4 study locations across Maryland, North Carolina, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ROSAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.